Zoetis Inc. (NYSE:ZTS) Shares Bought by Bogart Wealth LLC

Bogart Wealth LLC lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 1.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 32,561 shares of the company’s stock after acquiring an additional 372 shares during the period. Bogart Wealth LLC’s holdings in Zoetis were worth $6,362,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ZTS. Lafayette Investments Inc. grew its holdings in shares of Zoetis by 4.6% during the third quarter. Lafayette Investments Inc. now owns 1,716 shares of the company’s stock worth $335,000 after buying an additional 76 shares in the last quarter. Grimes & Company Inc. purchased a new stake in Zoetis in the 3rd quarter worth approximately $263,000. Cherry Creek Investment Advisors Inc. raised its holdings in Zoetis by 2.0% in the 3rd quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock valued at $590,000 after acquiring an additional 58 shares during the last quarter. Romano Brothers AND Company lifted its stake in shares of Zoetis by 2.3% during the 3rd quarter. Romano Brothers AND Company now owns 3,391 shares of the company’s stock worth $663,000 after purchasing an additional 75 shares during the period. Finally, International Assets Investment Management LLC boosted its holdings in shares of Zoetis by 41,235.7% during the third quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock worth $183,652,000 after purchasing an additional 937,700 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 4.1 %

Shares of NYSE ZTS traded down $7.78 on Thursday, hitting $181.21. The company had a trading volume of 2,411,680 shares, compared to its average volume of 2,507,419. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The firm has a market capitalization of $82.10 billion, a P/E ratio of 36.10, a PEG ratio of 2.94 and a beta of 0.89. The business has a 50 day moving average of $189.23 and a two-hundred day moving average of $177.58.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The firm had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. Zoetis’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.41 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 5.83 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be issued a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.95%. Zoetis’s dividend payout ratio is currently 33.86%.

Analyst Upgrades and Downgrades

Several research firms recently commented on ZTS. JPMorgan Chase & Co. upped their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Piper Sandler increased their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Stifel Nicolaus boosted their target price on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. BTIG Research increased their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.